Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;1(2):111-114.
doi: 10.4161/bact.1.2.14590.

Pros and cons of phage therapy

Affiliations

Pros and cons of phage therapy

Catherine Loc-Carrillo et al. Bacteriophage. 2011 Mar.

Abstract

Many publications list advantages and disadvantages associated with phage therapy, which is the use of bacterial viruses to combat populations of nuisance or pathogenic bacteria. The goal of this commentary is to discuss many of those issues in a single location. In terms of "Pros," for example, phages can be bactericidal, can increase in number over the course of treatment, tend to only minimally disrupt normal flora, are equally effective against antibiotic-sensitive and antibiotic-resistant bacteria, often are easily discovered, seem to be capable of disrupting bacterial biofilms, and can have low inherent toxicities. In addition to these assets, we consider aspects of phage therapy that can contribute to its safety, economics, or convenience, but in ways that are perhaps less essential to the phage potential to combat bacteria. For example, autonomous phage transfer between animals during veterinary application could provide convenience or economic advantages by decreasing the need for repeated phage application, but is not necessarily crucial to therapeutic success. We also consider possible disadvantages to phage use as antibacterial agents. These "Cons," however, tend to be relatively minor.

PubMed Disclaimer

References

    1. Summers WC. Bacteriophage therapy. Ann Rev Microbiol. 2001;55:437–451. doi: 10.1146/annurev.micro.55.1.437. - DOI - PubMed
    1. Abedon ST. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis. 2009;6:807–815. doi: 10.1089/fpd.2008.0242. - DOI - PubMed
    1. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11:28–47. - PubMed
    1. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591–595. - PubMed
    1. Carlton RM. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz) 1999;47:267–274. - PubMed

LinkOut - more resources